Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study.
Wei KangJessica J P ShamiVincent Ka Chun YanXuxiao YeJoseph Edgar BlaisXue LiVictor Ho Fun LeeCeline Sze Ling ChuiFrancisco Tsz Tsun LaiEric Yuk Fai WanCarlos King-Ho WongIan Chi Kei Ck WongEsther Wai Yin ChanPublished in: Journal of hematology & oncology (2022)
In this territory-wide cohort study of patients with cancer, the incidence of AESI following vaccination with two doses of either BNT162b2 or CoronaVac vaccines was low. The findings of this study can reassure clinicians and patients with cancer about the overall safety of BNT162b2 and CoronaVac in patients with cancer, which could increase the COVID-19 vaccination rate in this vulnerable group of patients.